GILEAD SCIENCES, INC.·4

Jun 11, 6:32 PM ET

Dickinson Andrew D 4

4 · GILEAD SCIENCES, INC. · Filed Jun 11, 2026

Research Summary

AI-generated summary of this filing

Updated

Gilead (GILD) CFO Andrew D. Dickinson Converts RSUs; 1,341 Shares Withheld

What Happened
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), had 2,796 restricted stock units (RSUs) convert to common shares on 2026-06-10. To cover tax withholding, 1,341 of those shares were surrendered at $121.48 per share for a withholding of $162,905. The remaining 1,455 shares were delivered to him (net value ≈ $176,753 based on the $121.48 per-share figure).

Key Details

  • Transaction date: 2026-06-10; Form 4 filed 2026-06-11 (timely filing).
  • Conversion: 2,796 RSUs converted to common stock (reported with code M).
  • Tax withholding: 1,341 shares withheld/ disposed (code F) at $121.48 each = $162,905.
  • Net shares delivered to insider: 1,455 shares (2,796 − 1,341). Net value ≈ $176,753 based on $121.48 per share (approximate).
  • Footnotes: F1 — each RSU equals the right to one share; F2 — these RSUs follow a 4-year vesting schedule (25% after one year, then 6.25% quarterly).
  • Shares owned after the transaction are not specified in the provided filing.

Context
This was a routine conversion/vesting of RSUs and a cashless-like withholding to satisfy tax obligations, not an open-market buy or sell. RSU vesting and withholding are common forms of executive compensation and do not necessarily signal a personal view on the stock. Code meanings: M = exercise/conversion of a derivative (here, RSU conversion), F = payment of tax liability via share withholding.

Insider Transaction Report

Form 4
Period: 2026-06-10
Dickinson Andrew D
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-10+2,796175,987 total
  • Tax Payment

    Common Stock

    2026-06-10$121.48/sh1,341$162,905174,646 total
  • Exercise/Conversion

    Restricted Stock Unit

    [F1][F2]
    2026-06-102,79627,851 total
    Common Stock (2,796 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
  • [F2]The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Signature
/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson|2026-06-11

Documents

1 file
  • 4
    wk-form4_1781217163.xmlPrimary

    FORM 4